Dr Lal PathLabs in focus as Citi sees 25% upside; check target price here

Citi upgraded Dr Lal Pathlabs Ltd to ‘buy’ from ‘sell’, targeting ₹1,650 per share. The diagnostics sector has stabilized, with expected 10-12% organic revenue growth and strong EBITDA margins.

Leave a Reply

Your email address will not be published. Required fields are marked *